Company Profile
Revolution Medicines Stock Price, News & Analysis
- Ticker:
- RVMD
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
197.81 USD (+0.26%)
Close
Last updated: August 6, 2026
32.2B USD
Market cap
Why the stock is moving
The latest company update was “Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress”. RVMD changed 0.26% and closed at $197.81 on Aug 6, 2026, indicating a relatively limited closing-price reaction to this earnings update.
Company overview
RAS(ON) Inhibitors
Revolution Medicines develops oral targeted therapies that bind active, GTP-loaded RAS proteins. Its portfolio covers multiple RAS mutations and combination strategies across pancreatic and lung cancers.
Daraxonrasib
Daraxonrasib is a multi-selective RAS(ON) inhibitor and the company's lead late-stage asset. It has demonstrated Phase 3 survival benefit in previously treated metastatic pancreatic cancer.
Pancreatic-Cancer Franchise
Beyond second-line disease, RASolute 304 evaluates daraxonrasib in resectable pancreatic cancer after surgery, while another registrational program addresses first-line metastatic disease.
Zoldonrasib
Zoldonrasib selectively targets RAS G12D and is being developed in lung cancer as monotherapy, with standard of care and in an inhibitor-doublet combination with daraxonrasib.
Elironrasib
Elironrasib is a covalent RAS G12C-selective inhibitor. Revolution Medicines is defining its registrational strategy within a broader mutation-specific portfolio.
Lung-Cancer Development
RASolve 301 evaluates daraxonrasib in previously treated non-small cell lung cancer, while RASolve 308 is a planned first-line Phase 3 study of zoldonrasib plus standard therapy.
Future catalysts
Detailed Phase 3 RASolute 302 results at an ASCO 2026 plenary session.
Global regulatory submissions, including a U.S. NDA, for daraxonrasib in previously treated pancreatic cancer.
Initiation of the Phase 3 RASolve 308 study in the first half of 2026.
Substantial completion of enrollment in RASolve 301 during 2026.
Initiation of a registrational zoldonrasib-plus-daraxonrasib study in the second half of 2026.
Recent news
- 01
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
Source: Revolution Medicines
- 02
Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026
Source: Revolution Medicines
- 03
- 04
European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
Source: Revolution Medicines
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Revolution Medicines (RVMD)?
Revolution Medicines (RVMD) most recently closed at 197.81 USD, a +0.26% move versus the previous session.
What is the market cap of Revolution Medicines (RVMD)?
Revolution Medicines currently has a market capitalization of 32.2B USD on BioPharmSignal.
What does Revolution Medicines do?
RAS(ON) Inhibitors Revolution Medicines develops oral targeted therapies that bind active, GTP-loaded RAS proteins. Its portfolio covers multiple RAS mutations and combination strategies across pancreatic and lung cancers. Daraxonrasib Daraxonrasib is a multi-selective RAS(ON) inhibitor and the company's lead late-stage asset. It has demonstrated Phase 3...
On which exchange is RVMD stock listed?
Revolution Medicines (RVMD) is associated with NASDAQ, United States, Biopharma.
What is Inhibitors?
RAS(ON) Inhibitors Revolution Medicines develops oral targeted therapies that bind active, GTP-loaded RAS proteins.
Which conditions is Revolution Medicines targeting with Inhibitors?
Revolution Medicines is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Revolution Medicines describe recent progress with Inhibitors?
Detailed Phase 3 RASolute 302 results at an ASCO 2026 plenary session. Global regulatory submissions, including a U.S. NDA, for daraxonrasib in previously treated pancreatic cancer. Initiation of the Phase 3 RASolve 308 study in the first half of 2026. Substantial completion of enrollment in RASolve 301 during 2026. Initiation of a registrational...
What is Revolution?
RAS(ON) Inhibitors Revolution Medicines develops oral targeted therapies that bind active, GTP-loaded RAS proteins.